Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2018 October;66(5) > Minerva Cardioangiologica 2018 October;66(5):543-6

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   

Minerva Cardioangiologica 2018 October;66(5):543-6

DOI: 10.23736/S0026-4725.18.04638-8

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Efficacy of Pycnogenol® supplementation in remission phases of Sjögren syndrome

Roberta LUZZI 1, 2, Gianni BELCARO 1, 2 , Shu HU 1, 2, Beatrice FERAGALLI 1, 2, Morio HOSOI 1, 2, Mark DUGALL 1, 2, Andrea LEDDA 1, 2

1 IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy; 2 International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy


PDF


BACKGROUND: The aim of this study was to evaluate the effects of Pycnogenol® supplementation in otherwise healthy subjects with Sjögren syndrome (SS) in a remission phase, who experienced persisting symptoms impairing their quality of life.
METHODS: The control group receiving only standard treatment was composed of 14 subjects, the supplement group included 16 subjects who used Pycnogenol® supplementation.
RESULTS: ESR and oxidative stress levels were high in all subjects at inclusion; both decreased significantly with supplementation (P<0.05). Pycnogenol® significantly improved the majority of symptoms (dry eyes and mouth dryness), diminishing the need for corticosteroids and other treatments.
CONCLUSIONS: Pycnogenol® supplementation in patients with SS in a remission phase may be effective to control inflammation and reduce symptoms.


KEY WORDS: Sjogren’s syndrome - Pycnogenol® - Dietary supplements, inflammation

top of page